Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of “Moderate Buy” from Analysts
Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year […]
Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year […]
